AbbVie And OSE Immunotherapeutics Enter Strategic Partnership To Develop A Novel Monoclonal Antibody For The Treatment Of Chronic Inflammation
Portfolio Pulse from Benzinga Newsdesk
AbbVie and OSE Immunotherapeutics have formed a strategic partnership to develop OSE-230, a monoclonal antibody for treating chronic inflammation. OSE Immunotherapeutics will receive an upfront payment of $48 million and could receive up to $665 million in milestone payments.
February 28, 2024 | 8:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie enters a strategic partnership with OSE Immunotherapeutics to develop OSE-230, a treatment for chronic inflammation, with potential milestone payments up to $665 million.
The partnership with OSE Immunotherapeutics to develop OSE-230 positions AbbVie at the forefront of chronic inflammation treatment. The significant financial commitment suggests a strong belief in the potential of OSE-230. This move could enhance AbbVie's portfolio in the inflammation and immunology segment, potentially leading to increased investor confidence and a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90